Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Samantha I. Liang; Zoe Quandt; Sara Wienke; Jing Wang; Sean Gordon; Reagan M. Barnett; Jude Masannat; Kyle Chang; Carin R. Espenschied; Katie Quinn; Kimberly C. Banks; Enjun Yang; John E. Connolly

doi:10.1158/2767-9764.29948093

August 20, 2025Open Access

Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper

Ask AI

Bookmark

Share

Key Points

Long-term clinical benefit from immune checkpoint inhibitors is associated with elevated ctdna tumor fraction, indicating a potential for effective treatment outcomes.
Increased tumor fractions were observed among patients treated with immune checkpoint inhibitors, suggesting a strong link to overall survival rates.
Observational analysis across various cancer types revealed significant variations in tumor fraction dynamics, enhancing understanding of treatment responses.
Findings highlight the promise of methylation-based biomarkers in personalizing cancer therapy, emphasizing the need for further validation in diverse cohorts.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Real-world analysis demonstrates ctdna tumor fraction correlates with clinical benefit in pan-cancer, suggesting its potential as a predictive biomarker.

Abstract

Swimmers Plots by cancer type

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af55d8ad7bf08b1eadc76f https://doi.org/10.1158/2767-9764.29948093

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers